Skip to main content

June 29, 2021

This blogpost from a former FDA insider on the power of the patient helps us understand how drug approval processes are informed by the patient experience, and why patient voices were so critical to the development and initial approval of Aduhelm.

Read: Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust? by James E. Valentine here.

Then read LuMind IDSC’s: FDA Approves Biogen’s Aduhelm, The First New Drug For Alzheimer’s Disease Since 2003


Learn More about Down syndrome and Alzheimer’s at LuMind IDSC

Register for myDSC and access our free digital library of Down syndrome resources